{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.9","value":"3.1"}]}],"title":"C-11 acetate PET CT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.8","value":"3.3"}]}],"title":"C-11 acetate PET MRI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.0","value":"1.9"}]}],"title":"18 FDG PET CT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.9","value":"2.0"}]}],"title":"18 FDG PET MRI"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"The visual image analysis scale has a range of 0-4: (0 no uptake; 1 benign, 2 probably benign, 3 probably malignant, 4 malignant).","dispersionType":"Standard Deviation","groups":[{"description":"New diagnosis, high risk smoldering MM, relapse as defined by investigator. Participants received 4 different techniques of diagnosis: Fludeoxyglucose (F-18 FDG) PET/MRI, Sodium Acetate (C-11 acetate) PET/CT, C-11 PET/MRI, and F-18 FDG PET/CT. Each participant received both PET drugs by both diagnostic techniques and is therefore included in the analysis population for the four reporting groups.\n\nFludeoxyglucose: Route of administration was intravenous. Dose of each injection was the standard 5 to 10 millicurie (mCi).\n\nSodium Acetate C11: Route of administration was intravenous. Dose of each injection was 10 mCi (370 MBq).","id":"OG000","title":"Multiple Myeloma (MM) Patients"}],"paramType":"MEAN","populationDescription":"Each participant received both PET drugs by both diagnostic techniques (scans) and is therefore included in the analysis population for the four reporting groups.","reportingStatus":"POSTED","timeFrame":"Approximately one month after Day 2","title":"Visual Image Analysis of Detected Multiple Myeloma Lesions","type":"SECONDARY","unitOfMeasure":"score on a scale"}